MaxCyte, Inc. (LON:MXCT – Get Free Report) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 1.55 and traded as low as GBX 1.39. MaxCyte shares last traded at GBX 1.44, with a volume of 749,867 shares traded.
MaxCyte Stock Performance
The company has a market cap of £1.53 million, a PE ratio of -0.04 and a beta of 1.13. The stock has a 50 day simple moving average of GBX 1.55 and a two-hundred day simple moving average of GBX 55.73. The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
See Also
- Five stocks we like better than MaxCyte
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Occidental Petroleum is a Buy in Q4 2025
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Beaten-Down Stocks With Rebound Potential This Earnings Season
- Retail Stocks Investing, Explained
- Amazon Is One of the Clearest Buys If the Market Dips Again
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
